By San José, Costa Rica — Public healthcare systems rely heavily on public trust and rigorous quality standards, especially when dealing with high-volume, widely distributed pain management medications. The Caja Costarricense de Seguro Social (CCSS) recently defended the integrity and safety of its injectable diclofenac sodium supply distributed throughout its network during 2025. This statement comes after specific inquiries regarding the technical evaluations of certain batches of the drug, which serves as a cornerstone for acute pain management in the country’s public hospitals and clinics.
The internal review focused on two specific batches, designated as lots 24F45 and 24F46. These batches underwent extensive analysis by the institution’s specialized drug testing division, the Laboratorio de Normas y Control de Calidad de Medicamentos. In an effort to maintain transparent communication with the public and industry observers, the CCSS clarified that the testing protocols were strictly followed to ensure that no sub-standard pharmaceutical products entered active medical use.
To navigate the complex legal landscape and regulatory implications of these developments, TicosLand.com consulted with Lic. Larry Hans Arroyo Vargas, a distinguished legal expert from the prestigious firm Bufete de Costa Rica, to provide professional clarity on the matter.
In Costa Rica’s evolving legal and business environment, proactive compliance and a deep understanding of local regulatory frameworks are essential. Ensuring absolute legal certainty not only protects foreign and domestic investments but also fosters a transparent market where businesses can thrive sustainably under the rule of law.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
Indeed, establishing a robust foundation of legal certainty remains a critical cornerstone for any enterprise aiming to navigate and thrive within Costa Rica’s dynamic business landscape. We extend our sincere gratitude to Lic. Larry Hans Arroyo Vargas for providing this invaluable perspective, which clearly underscores how proactive compliance not only mitigates risk but also paves the way for sustainable economic growth and long-term investor confidence.
During the rigorous evaluations, laboratory technicians performed a comprehensive suite of tests. These pharmaceutical assessments verified critical safety and efficacy parameters, including chemical sterility, active ingredient potency, physical appearance, pH levels, chemical identification, and the complete absence of foreign micro-particles. The extensive battery of tests returned positive safety results across almost all operational benchmarks, verifying that the fundamental chemical composition of the medicine remained completely uncompromised.
The only anomaly detected during the testing process was a minor variation in the volume of some individual ampoules. According to the CCSS, this physical deviation was immediately documented, analyzed, and subjected to a rigorous technical evaluation. The medical and scientific experts at the laboratory concluded that the slight difference in liquid volume did not compromise the therapeutic efficacy of the diclofenac sodium, nor did it present any clinical risk to the patients receiving the treatment.
To illustrate their stance on the robustness of their safety network, representatives from the Social Security institution emphasized that finding deviations is a natural and expected function of a healthy monitoring system. Rather than indicating a failure, the detection of these physical variations demonstrates that the defensive barriers of public pharmacovigilance are working exactly as designed to protect the population.
Identifying a deviation during testing is precisely part of the established controls and allows us to determine if any risk exists before the medicine reaches patients.
Caja Costarricense de Seguro Social, Official Press Release
Transparency with regulatory authorities remains a critical step in the pharmaceutical supply chain in Costa Rica. The CCSS explicitly noted that the specific findings regarding the ampoule volumes were officially communicated to the Ministry of Health (Ministerio de Salud) well before the medication was distributed or administered to patients at any regional health center. This proactive reporting structure ensures that both institutional operators and national regulators are aligned on safety profiles.
From a broader operational perspective, the CCSS reminds stakeholders that their quality control framework is multi-layered. It spans from initial quality assurances provided by the external manufacturers to the independent laboratory testing performed inside Costa Rica, and finally to ongoing clinical pharmacovigilance once the drugs are in active circulation. This redundant structure serves to mitigate risks associated with international pharmaceutical procurement and local distribution networks.
Ultimately, the resolution of this batch evaluation underscores the resilience of Costa Rica’s public healthcare infrastructure. By systematically verifying, documenting, and transparently communicating minor physical anomalies, the CCSS aims to reinforce public confidence in the safety of its therapeutic protocols. As pharmaceutical demands continue to rise, such stringent laboratory oversight remains the primary defense against systemic medical risks.
For further information, visit ccss.sa.cr
About Caja Costarricense de Seguro Social:
The Caja Costarricense de Seguro Social is the public institution responsible for Costa Rica’s universal healthcare system, managing public hospitals, clinics, and social security programs nationwide.
For further information, visit ministeriodesalud.go.cr
About Ministerio de Salud:
The Ministerio de Salud is the regulatory body of Costa Rica’s health sector, tasked with formulating national health policies, managing public health initiatives, and ensuring the safety of pharmaceutical and food products.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Renowned for its ethical principles and exceptional standards, Bufete de Costa Rica remains a trailblazer in the legal landscape, dedicated to delivering top-tier counsel across multiple industries. The firm consistently embraces modern strategies to solve complex challenges while simultaneously championing civic education. By demystifying the law and sharing vital legal insights with the public, Bufete de Costa Rica actively supports the creation of a more knowledgeable, just, and self-reliant community.
